How do I find recruiting Leukemia clinical trials?

Browse the actively recruiting Leukemia studies listed on this page, or take an assessment to see trials you may qualify for based on your profile.

Are Leukemia clinical trials free to join?

Costs, travel support, and any payment for taking part vary by study. Ask the study team what is covered before you decide to join.

Who can take part in a Leukemia clinical trial?

Each study has its own eligibility criteria (for example age, disease stage, and prior treatments). This page is general information and not medical advice; discuss any specific trial with your healthcare provider to confirm whether it is appropriate for you.

Leukemia Clinical Trials

Leukemia clinical trials evaluate new drugs, immunotherapies, radiation approaches, and combination treatments for leukemia. Corterve aggregates actively recruiting Leukemia studies from the public ClinicalTrials.gov registry so you can browse them by location and eligibility. Many oncology trials enroll patients at different stages of disease, including newly diagnosed and previously treated. This is general information, not medical advice — review any study with your oncology care team before enrolling.

Browse all Leukemia trials Take the assessment

Recruiting Leukemia studies

Chart Review Study of Chronic Myelogenous Leukemia (CML) Patients Treated With Imatinib Outside of a Clinical Trial
NCT00816114M.D. Anderson Cancer CenterChronic Myelogenous LeukemiaHouston, Texas
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
NCT05554393PHASE2National Cancer Institute (NCI)Acute Myeloid LeukemiaBirmingham, Alabama
Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATCH Treatment Trial)
NCT06917911PHASE2National Cancer Institute (NCI)Core Binding Factor Acute Myeloid LeukemiaBirmingham, Alabama
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
NCT05091424PHASE1Hoffmann-La RocheChronic Lymphocytic Leukemia or Small Lymphocytic LymphomaRochester, Minnesota
Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)
NCT07223814PHASE3Stichting Hemato-Oncologie voor Volwassenen NederlandAcute Myeloid LeukemiaLos Angeles, California
Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
NCT07437950PHASE2National Cancer Institute (NCI)Acute Myeloid LeukemiaCoeur d'Alene, Idaho
A Study of CHM-029 in Participants With NPM1 Mutated, KMT2A or NUP98 Rearranged AML
NCT07751991PHASE1Charm TherapeuticsAML (Acute Myeloid Leukemia)Duarte, California
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
NCT06672146PHASE2National Cancer Institute (NCI)Acute Myeloid LeukemiaTucson, Arizona
Long-term Evaluation and Follow-up Care of Patients Treated With Stem Cell Transplants
NCT00106925National Heart, Lung, and Blood Institute (NHLBI)Graft-versus-leukemiaBethesda, Maryland
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
NCT06317649PHASE2National Cancer Institute (NCI)Acute Myeloid LeukemiaBirmingham, Alabama
A Multicenter Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-Cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymph...
NCT05621291NANational Cancer Institute (NCI)B-AllLos Angeles, California
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
NCT06317662PHASE2National Cancer Institute (NCI)Acute Leukemia of Ambiguous LineageBirmingham, Alabama

See all 592 recruiting trials →

Leukemia trials by state

Leukemia trials by metro

Frequently asked questions

How do I find recruiting Leukemia clinical trials?: Browse the actively recruiting Leukemia studies listed on this page, or take an assessment to see trials you may qualify for based on your profile.
Are Leukemia clinical trials free to join?: Costs, travel support, and any payment for taking part vary by study. Ask the study team what is covered before you decide to join.
Who can take part in a Leukemia clinical trial?: Each study has its own eligibility criteria (for example age, disease stage, and prior treatments). This page is general information and not medical advice; discuss any specific trial with your healthcare provider to confirm whether it is appropriate for you.